* patients \< 12 years old. * pregnant females. * patients with renal impairment with creatinine clearance \< 30 ml/min. * patients with malignancies particularly hepatocellular carcinoma (hcc). * patients using favipiravir or lopinavir-ritonavir, as the co-administration of these drugs with sofosbuvir/ledipasvir has not been studied. * patients with decompensated liver cirrhosis (child-pugh score b and c).

* patients \< 12 years old. * pregnant females. * patients with renal impairment with creatinine clearance \< 30 ml/min. * patients with malignancies particularly hepatocellular carcinoma (hcc). * patients using favipiravir or lopinavir-ritonavir, as the co-administration of these drugs with sofosbuvir/ledipasvir has not been studied. * patients with decompensated liver cirrhosis (child-pugh score b and c).

- patients < 12 years old. - pregnant females. - patients with renal impairment with creatinine clearance < 30 ml/min. - patients with malignancies particularly hepatocellular carcinoma (hcc). - patients using favipiravir or lopinavir-ritonavir, as the co-administration of these drugs with sofosbuvir/ledipasvir has not been studied. - patients with decompensated liver cirrhosis (child-pugh score b and c).

- patients < 12 years old. - pregnant females. - patients with renal impairment with creatinine clearance < 30 ml/min. - patients with malignancies particularly hepatocellular carcinoma (hcc). - patients using favipiravir or lopinavir-ritonavir, as the co-administration of these drugs with sofosbuvir/ledipasvir has not been studied. - patients with decompensated liver cirrhosis (child-pugh score b and c).